Protagonist Therapeutics (PTGX) Posts Earnings Results, Misses Expectations By $0.01 EPS

Protagonist Therapeutics (NASDAQ:PTGX) released its quarterly earnings results on Tuesday. The company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01), Fidelity Earnings reports. The business had revenue of $6.12 million for the quarter, compared to the consensus estimate of $6.35 million. Protagonist Therapeutics had a negative net margin of 56.92% and a negative return on equity of 24.16%.

Shares of PTGX traded up $0.15 during mid-day trading on Wednesday, reaching $8.84. 12,336 shares of the company’s stock traded hands, compared to its average volume of 74,693. The stock has a market cap of $194.37 million, a PE ratio of -4.26 and a beta of 3.44. Protagonist Therapeutics has a 12 month low of $5.50 and a 12 month high of $23.97.

A number of equities research analysts have recently weighed in on the company. ValuEngine raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 18th. Zacks Investment Research raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Finally, Leerink Swann lifted their price target on Protagonist Therapeutics from $13.00 to $21.00 and gave the company an “outperform” rating in a report on Monday, August 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Protagonist Therapeutics has a consensus rating of “Hold” and a consensus target price of $22.00.

An institutional investor recently raised its position in Protagonist Therapeutics stock. Bank of New York Mellon Corp increased its position in shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) by 26.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,269 shares of the company’s stock after purchasing an additional 13,303 shares during the period. Bank of New York Mellon Corp owned 0.30% of Protagonist Therapeutics worth $426,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 57.34% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/11/07/protagonist-therapeutics-ptgx-posts-earnings-results-misses-expectations-by-0-01-eps.html.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.

See Also: What is a Market Correction?

Earnings History for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply